Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
27
datasets available to search
ShareScore release 0.9.0
Dataset results
27 results for “drug resistance mutations”
PfCRT mutations conferring piperaquine resistance in falciparum malaria shape the kinetics of quinoline drug binding and transport
<p>These data were generated to investigate the effect of point mutations in PfCRT on the kinetics of chloroquine and piperaquine binding and transport. The protein confers resistance to a range of quinoline and quinoline-like antimalarials after the acquisition of certain amino acid substitutions, which occurs as a result of improper antimalarial use. The change in prescription from chloroquine (CQ) to piperaquine (PPQ) in Southeast Asian countries led to the emergence of a ninth mutation over the PfCRT Dd2 isoform, which renders the parasites resistant to piperaquine but re-sensitizes them to chloroquine. Despite structural information, how these individual mutations influence such opposing changes in the parasite's susceptibility to the aforementioned drugs remains unknown. Here, we show by biochemical studies that any of the piperaquine resistance-conferring mutations H97Y, F145I, M343L or G353V, either reduce the affinity of PfCRT Dd2 for CQ (Km) or reduce the efficiency of the transport cycle (Vmax). In parallel, they increase the Vmax, reduce the Km, or do both, in the case of PPQ transport. We also probed the binding cavity of PfCRT Dd2 and that of PfCRT Dd2_F145I, and found that it can readily bind both CQ and PPQ simultaneously, in a partial noncompetitive mechanism. We confirmed the latter finding through molecular docking and molecular dynamics simulations, describing for the first time the binding sites for both drugs in the cavity of PfCRT Dd2. With this, we found that the pocket where CQ binds seems to require an aromatic side chain, which is normally provided by F145, or by Y97 in the PPQ resistance-conferring H97Y mutant. Lastly, we generated an unnatural double mutant carrying both the H97Y and the F145I mutations. The engineered transporter displayed non-Michaelis-Menten kinetics both for CQ and PPQ transport and instead revealed sigmoidal kinetics, typical of proteins that bind substrate cooperatively. We thus provide new insights into the organization of the substrate-binding cavity of PfCRT and into the evolution of PfCRT.</p>
Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth
ClinicalTrials.gov study NCT00109590. IPD Sharing: Not stated. Countries: 1. Publications: 6.
PfCRT mutations conferring piperaquine resistance in falciparum malaria shape the kinetics of quinoline drug binding and transport
Open the record for dataset details and reuse information.
Primary and Secondary Drug Resistance Mutations (DRMs) in HIV As a Risk Factor of Failure of ART, Including Two Drugs Based Regimens.
ClinicalTrials.gov study NCT06661317. IPD Sharing: NO. Countries: 1. Publications: 12.
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
ClinicalTrials.gov study NCT04197713. IPD Sharing: YES. Countries: 1. Publications: 0.
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
ClinicalTrials.gov study NCT06044792. IPD Sharing: NO. Countries: 0. Publications: 9.
Piperaquine-resistant PfCRT mutations differentially impact drug transport, hemoglobin catabolism and parasite physiology in Plasmodium falciparum asexual blood stages
GEO Series GSE205515. Plasmodium falciparum. 13 samples. Type: Expression profiling by array.
Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs
GEO Series GSE164664. Homo sapiens. 145 samples. Type: Other; Expression profiling by high throughput sequencing.
The NSD2 p.E1099K Mutation is Enriched at Relapse and Confers Drug Resistance in a Cell Context Dependent Manner in Pediatric Acute Lymphoblastic Leukemia
GEO Series GSE149159. Homo sapiens. 83 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
Lentiviral-driven discovery of cancer drug resistance mutations
GEO Series GSE180965. Homo sapiens. 120 samples. Type: Expression profiling by high throughput sequencing.
Evolution of drug resistance in cancer cells involves generation of numerous mutations in non-coding genome that reduces the chances of DNA breaks
GEO Series GSE189366. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs [lenti]
GEO Series GSE164663. Homo sapiens. 23 samples. Type: Other.
Identification of drug- resistance mutations in majority and minority subpopulations of HIV-1 quasispecies
GEO Series GSE90621. Simian-Human immunodeficiency virus. 470 samples. Type: Genome variation profiling by array.
Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
GEO Series GSE216871. Mus musculus. 16 samples. Type: Expression profiling by high throughput sequencing.
The NSD2 p.E1099K Mutation is Enriched at Relapse and Confers Drug Resistance in a Cell Context Dependent Manner in Pediatric Acute Lymphoblastic Leukemia (RNA-Seq)
GEO Series GSE149158. Homo sapiens. 42 samples. Type: Expression profiling by high throughput sequencing.
Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs [umi]
GEO Series GSE164661. Homo sapiens. 2 samples. Type: Other.
Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance: elevated P2RX7 levels indicate response to targeted therapy
GEO Series GSE230538. Homo sapiens. 16 samples. Type: Expression profiling by high throughput sequencing.
Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy
ClinicalTrials.gov study NCT04040075. IPD Sharing: NO. Countries: 1. Publications: 0.
Molecular Characteristics of Hepatitis B Virus Integration, Mutation, and Drug Resistance
ClinicalTrials.gov study NCT06779864. IPD Sharing: NO. Countries: 1. Publications: 0.
Dynamics of Drug Resistance-associated Mutations in HIV-1 DNA Reverse Transcriptase Clearance During Effective Antiretroviral Therapy
ClinicalTrials.gov study NCT04448158. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.